XTLBNasdaqPharmaceutical Preparations
XTL BIOPHARMACEUTICALS LTD
Financials through fiscal 2024, year ended Dec 31, 2024Last filing: 20-F on Jun 30, 2026
$1.96−0.00 (-0.01%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$3.08 (−61.11%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Split
XTL BIOPHARMACEUTICALS LTD reported revenue of $451.00K for fiscal 2024. Free cash flow was -$1.67M.
Revenue
$451.00K
FY2024
Operating income
-$2.17M
FY2024
Free cash flow
-$1.67M
FY2024
EPS, diluted
-$0.00
FY2024
Key statistics
Valuation at the latest close; fundamentals over fiscal 2024, balances at Dec 31, 2024
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $451.00K
- EPS, diluted
- -$0.00
- Free cash flow
- -$1.67M
Eleven years at a glance
Fiscal years 2014 to 2024, USD
Revenue
$451.00K
Gross profit
$3.00K
Operating income
-$2.17M
Net income
–
EPS, diluted
-$0.00
Free cash flow
-$1.67M
Reported period